Central venous catheter-associated Nocardia bacteremia in cancer patients

Emerg Infect Dis. 2011 Sep;17(9):1651-8. doi: 10.3201/eid1709.101810.

Abstract

Central venous catheters, often needed by cancer patients, can be the source of Nocardia bacteremia. We evaluated the clinical characteristics and outcomes of 17 cancer patients with Nocardia bacteremia. For 10 patients, the bacteremia was associated with the catheter; for the other 7, it was a disseminated infection. N. nova complex was the leading cause of bacteremia. Nocardia promoted heavy biofilm formation on the surface of central venous catheter segments tested in an in vitro biofilm model. Trimethoprim- and minocycline-based lock solutions had potent in vitro activity against biofilm growth. Patients with Nocardia central venous catheter-associated bloodstream infections responded well to catheter removal and antimicrobial drug therapy, whereas those with disseminated bacteremia had poor prognoses.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / complications
  • Bacteremia / drug therapy
  • Bacteremia / microbiology*
  • Biofilms*
  • Catheterization, Central Venous / adverse effects*
  • Catheters, Indwelling / microbiology*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Microscopy, Electron, Scanning
  • Neoplasms / complications
  • Neoplasms / therapy*
  • Nocardia Infections / complications
  • Nocardia Infections / drug therapy
  • Nocardia Infections / microbiology*
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • beta-Lactams / therapeutic use

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • Trimethoprim, Sulfamethoxazole Drug Combination